Futura Strikes Deal With Menarini To Commercialize MED3000 ED Gel In South Korea

South Korean erectile dysfunction sufferers may soon be able to acess Futura Medical's drug-free MED3000 treatment thanks to a deal with Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, for exclusive commercialization rights in the country. 

Flag of South Korea flies in front of a blue sky
• Source: Shutterstock

Menarini Korea Limited, a wholly owned subsidiary of Italy’s Menarini Group, has struck a deal with UK R&D specialist Futura Medical plc for the exclusive rights to commercialize the latter’s topical, gel-based erectile dysfunction treatment MED3000 in South Korea.

More from Asia

More from Geography